GOVX - GeoVax Labs Inc logo

GeoVax Labs Inc

GOVX

GeoVax Labs develops human vaccines and immunotherapies targeting infectious diseases like COVID-19, HIV, and Ebola, along with therapeutic vaccines for solid tumors. Its key projects include GEO-CM04S1 and Gedeptin, aimed at broad health challenges.

โš•๏ธ Healthcare NASDAQ Listed 1999 $ USD
$1,000 invested 30 years ago โ†’$0today

Score Overview

1 Year
Score
Net Growth4.84%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth-100.00%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score4.6
Net Growth-10.22%
Net Trend80%
Net Income Consistencyโ€”
Rev Growth-100.00%
Rev Trend20%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-4x
Net Trend60%
Net Income Consistency
Rev Growth-100.00%
Rev Trend40%
Revenue Consistency
20 Years
Score2.2
Net Growth-32x
Net Trend60%
Net Income Consistency
Rev Growth-100.00%
Rev Trend40%
Revenue Consistency
All Time
Score
Net Growth-119.48%
Net Trend63%
Net Income Consistency
Rev Growth-100.00%
Rev Trend39%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where GeoVax Labs Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 30 years of fundamentals. GOVX does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-29
$ 0.35โ€”
1 Year2025-09-29
$ 15.72-97.76%
5 Years2021-09-29
$ 1.69K-99.98%
10 Years2016-09-29
$ 1000K-100.00%
20 Years2006-09-29
$ 1000K-100.00%
30 Years1996-09-27
$ 1000K-100.00%
All Time1999-04-09
$ 1000K-100.00%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 0.00-$ 20M$ 3M
2025$ 2M-$ 21M$ 3M
2024$ 3M-$ 24M$ 5M
2023$ 0.00-$ 25M$ 6M
2022$ 81K-$ 14M$ 27M
2021$ 385K-$ 18M$ 11M
2020$ 1M-$ 2M$ 9M
2019$ 1M-$ 2M$ 283.34K
2018$ 963K-$ 2M$ 260K
2017$ 1M-$ 2M$ 312.73K
2016$ 828.92K-$ 3M$ 454.03K
2015$ 428.08K-$ 2M$ 1M
2014$ 882.96K-$ 2M$ 1M
2013$ 2M-$ 2M$ 2M
2012$ 2M-$ 2M$ 1M
2011$ 4M-$ 2M$ 1M
2010$ 5M-$ 2M$ 1M
2009$ 3M-$ 3M$ 3M
2008$ 2M-$ 3M$ 2M
2007$ 237K-$ 4M$ 1M
2006$ 852.9K-$ 584.17K$ 2M
2005-$ 1M$ 78.38K
2004-$ 2M$ 7.83K
2003-$ 3M$ 326.00
2002$ 180.24K-$ 618.14K
2001$ 2M-$ 13M$ 725.36K
2000$ 859.84K-$ 8M$ 2M
IPO1999$ 2M-$ 9M$ 31.09K
GOVX - GeoVax Labs Inc logo

GeoVax Labs Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 1M to $ 2M and net income went from -$ 2M to -$ 21M. Revenue increased in 1 of those 5 years; net income in 4.

Across GeoVax Labs Inc's full reported history, from 1999 to 2025, revenue grew from $ 2M to $ 2M and net income went from -$ 9M to -$ 21M. Revenue increased in 39% of the years measured; net income in 63%.

GeoVax Labs Inc currently holds a 20-year HDB Score of 2.2 out of 10. How the HDB Score is calculated.

Membership

Explore GOVX with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies